Pangaea OncologyXMAD:PANG 67 OCF Margin % is -17.03% as of Dec. 2025. GuruFocus rates XMAD:PANG with a GF Score™ of 67/100 and a GF Value™ of €2.14 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Pangaea Oncology ranks worse than 69.12% on this metric.
The historical rank and industry rank for Pangaea Oncology's OCF Margin % or its related term are showing as below:
XMAD:PANG'
s OCF Margin % Range Over the Past 10 Years
Min: -247.14 Med: -62.48 Max: -17.35
Current: -17.35
During the past 13 years, the highest OCF Margin % of Pangaea Oncology was -17.35%. The lowest was -247.14%. And the median was -62.48%.
XMAD:PANG's OCF Margin % is ranked worse than 69.12% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: 4.755
vs XMAD:PANG: -17.35
Pangaea Oncology OCF Margin % Related Terms
Pangaea Oncology OCF Margin % Historical Data
* Premium members only.
The historical data trend for Pangaea Oncology's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:PANG vs TMO, DHR, IDXX: OCF Margin % Comparison
For the Diagnostics & Research subindustry, Pangaea Oncology's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pangaea Oncology OCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Pangaea Oncology's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Pangaea Oncology's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pangaea Oncology (XMAD:PANG) has a OCF Margin % of -17.03% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Pangaea Oncology and its competitors. According to the industry distribution chart, Pangaea Oncology ranks #141 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 69.1%.
Is Pangaea Oncology's OCF Margin % too high?
Pangaea Oncology's current OCF Margin % is -17.03%. Based on the distribution chart, Pangaea Oncology ranks #141 out of 204 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Pangaea Oncology has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pangaea Oncology's OCF Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Pangaea Oncology ranks #141 out of 204 companies for OCF Margin %. This places Pangaea Oncology in the lower half of its industry. The industry median OCF Margin % is 4.76. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Diagnostics & Research company?
The median OCF Margin % among Medical Diagnostics & Research companies is 4.76, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Pangaea Oncology and its competitors. For the Medical Diagnostics & Research industry, the median OCF Margin % is 4.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pangaea Oncology's current OCF Margin % is -17.03%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pangaea Oncology stock overvalued right now?
Based on GuruFocus' analysis, Pangaea Oncology (XMAD:PANG) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.14, compared to a current price of €1.56 — trading 27.1% below its estimated fair value. The current OCF Margin % is -17.03%. Pangaea Oncology's overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Pangaea Oncology (XMAD:PANG), the current OCF Margin % is -17.03% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pangaea Oncology (XMAD:PANG) Overvalued in 2026?
Based on GuruFocus' analysis, Pangaea Oncology stock appears to be undervalued.
The current stock price of €1.56 is trading 27.1% below its estimated GF Value™ of €2.14.
GuruFocus considers Pangaea Oncology to be Modestly Undervalued.
Key valuation signals for XMAD:PANG:
OCF Margin %: -17.03%
GF Value™: €2.14 vs. price of €1.56 (27.1% below fair value)
No single metric tells the full story. See the XMAD:PANG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pangaea Oncology SA is a medical services company. The company provides a wide range of services to cancer patients, as well as global pharmaceutical and biotech clients, in the fields of molecular diagnostics, clinical trials, in vitro drug profiling, dx platform validation, and biomarker discovery. The company has aggregated its operations into two segments, Clinical Care division and Diagnostic and Research and Development services division. Clinical Care division delivers medical oncology services and related activities. Diagnostic and Research and Development services division provides diagnostic and in-vitro services.
67GF Score
Get the complete analysis for XMAD:PANG
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:PANG has been successfully added to your 
